Enhabit Reports Fourth Quarter Results and Issues Full-Year 2025 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Leerink Partners on Enhabit Home Health & Hospice (EHAB): 'Very Modest EBITDA Beat with 2025 Guidance Mostly In-Line'
March 6, 2025 1:21 PM ESTLeerink Partners analyst Whit Mayo reiterated a Market Perform rating on Enhabit Home Health & Hospice (NYSE: EHAB).
The analyst comments "Reiterate Market Perform rating. 4Q results look fine with in-line revs, a modest EBITDA beat (+2%), and 2025 guided largely in-line. Home Health again... More
Jefferies Defends Enhabit Home Health & Hospice (EHAB): 'Sell-Off Unwarranted Given Stabilizing KPIs, Defensiveness vs DC, Valuation'
March 6, 2025 1:18 PM ESTJefferies analyst Brian Tanquilut reiterated a Buy rating and $9.50 price target on Enhabit Home Health & Hospice (NYSE: EHAB)
The analyst comments "We maintain our Buy on EHAB and point to Q4 results being "good enough" (slight EBITDA beat) and FY25 guidance bracketing consensus... More
